Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
Egypt
Inflammatory breast cancer
Morocco
Risk factor
Tunisia
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
24
12
2019
accepted:
06
08
2020
pubmed:
3
9
2020
medline:
24
6
2021
entrez:
3
9
2020
Statut:
ppublish
Résumé
Studies of the etiology of inflammatory breast cancer (IBC), a rare but aggressive breast cancer, have been hampered by limited risk factor information. We extend previous studies by evaluating a broader range of risk factors. Between 2009 and 2015, we conducted a case-control study of IBC at six centers in Egypt, Tunisia, and Morocco; enrolled were 267 IBC cases and for comparison 274 non-IBC cases and 275 controls, both matched on age and geographic area to the IBC cases. We administered questionnaires and collected anthropometric measurements for all study subjects. We used multiple imputation methods to account for missing values and calculated odds ratios (ORs) and 95% confidence intervals (CIs) using polytomous logistic regression comparing each of the two case groups to the controls, with statistical tests for the difference between the coefficients for the two case groups. After multivariable adjustment, a livebirth within the previous 2 years (OR 4.6; 95% CI 1.8 to 11.7) and diabetes (OR 1.8; 95% CI 1.1 to 3.0) were associated with increased risk of IBC, but not non-IBC (OR 0.9; 95% CI 0.3 to 2.5 and OR 0.9; 95% CI 0.5 to 1.6 for livebirth and diabetes, respectively). A family history of breast cancer, inflammatory-like breast problems, breast trauma, and low socioeconomic status were associated with increased risk of both tumor types. We identified novel risk factors for IBC and non-IBC, some of which preferentially increased risk of IBC compared to non-IBC. Upon confirmation, these findings could help illuminate the etiology and aid in prevention of this aggressive cancer.
Identifiants
pubmed: 32876910
doi: 10.1007/s10549-020-05864-3
pii: 10.1007/s10549-020-05864-3
pmc: PMC10440960
mid: NIHMS1889247
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-558Subventions
Organisme : NCI NIH HHS
ID : R25 CA112383
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Organisme : NIH HHS
ID : Grant R25 CA112383
Pays : United States
Références
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):155-65
pubmed: 22028401
Breast Cancer Res Treat. 2006 Feb;95(3):243-55
pubmed: 16261404
Cancer. 2010 Jun 1;116(11 Suppl):2748-54
pubmed: 20503405
Breast. 2006 Jun;15(3):355-62
pubmed: 16198566
Int J Cancer. 2009 Feb 1;124(3):698-712
pubmed: 18988226
J Natl Cancer Inst. 2013 Sep 18;105(18):1373-84
pubmed: 24046390
Epidemiology. 2009 Sep;20(5):747-51
pubmed: 19688877
PLoS One. 2012;7(12):e51446
pubmed: 23236502
Oncogene. 2002 May 16;21(22):3631-43
pubmed: 12032865
Breast Cancer Res Treat. 2019 Jul;176(2):407-417
pubmed: 31006821
Cancer. 2010 Jun 1;116(11 Suppl):2730-5
pubmed: 20503401
Breast Dis. 2005-2006;22:9-23
pubmed: 16735783
Mediators Inflamm. 2017;2017:4754827
pubmed: 28607534
Lancet Oncol. 2016 May;17(5):544-6
pubmed: 27032300
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):862-868
pubmed: 28087608
PLoS One. 2018 Jan 16;13(1):e0191333
pubmed: 29338058
Cytokine. 2002 May 21;18(4):191-8
pubmed: 12126641
Int J Cancer. 1997 Sep 4;72(5):720-7
pubmed: 9311584
Lancet Oncol. 2015 Nov;16(15):e568-e576
pubmed: 26545845
Oncotarget. 2017 Dec 14;9(6):7204-7218
pubmed: 29467962
Breast Cancer Res Treat. 2014 Feb;144(1):1-10
pubmed: 24477977
Cancer. 1980 Dec 15;46(12):2741-6
pubmed: 7448713
Bull World Health Organ. 2005 Nov;83(11):829-36
pubmed: 16302039
Clin Cancer Res. 2005 Nov 1;11(21):7637-42
pubmed: 16278382
Cancer Causes Control. 2016 Mar;27(3):359-66
pubmed: 26797453
Eur J Cancer. 2014 Jul;50(10):1808-1818
pubmed: 24767469
BMC Cancer. 2016 May 26;16:334
pubmed: 27229687
Breast. 2017 Oct;35:136-141
pubmed: 28732325
Clin Cancer Res. 2007 May 15;13(10):2825-30
pubmed: 17504979
Curr Opin Pharmacol. 2016 Aug;29:77-89
pubmed: 27429211
J Natl Cancer Inst. 2013 Sep 18;105(18):1340-2
pubmed: 24046389
Cancer Causes Control. 2010 Mar;21(3):393-7
pubmed: 19921444
Br J Surg. 2013 Oct;100(11):1421-9
pubmed: 24037561
Cancer Epidemiol. 2011 Jun;35(3):217-34
pubmed: 21470929
Ann Intern Med. 2019 Jan 1;170(1):22-30
pubmed: 30534999
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
pubmed: 15998949
Breast Cancer Res Treat. 1985;6(2):137-44
pubmed: 4052640
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
Breast Cancer Res. 2000;2(6):423-9
pubmed: 11250736
Int J Environ Res Public Health. 2017 Apr 11;14(4):
pubmed: 28398259
Breastfeed Med. 2015 Apr;10(3):175-82
pubmed: 25785349
Med Oncol. 2013 Mar;30(1):480
pubmed: 23377925
Cancer Med. 2012 Dec;1(3):338-49
pubmed: 23342283
J Clin Oncol. 1998 Dec;16(12):3731-5
pubmed: 9850015
Eur J Cancer Prev. 2002 Jun;11(3):307-11
pubmed: 12131664
Semin Oncol. 2008 Feb;35(1):17-24
pubmed: 18308142